Abstract
Purpose
Standard treatment for patients with primary central nervous system (CNS) lymphoma involves combining high-dose methotrexate-based chemotherapy and radiation. However, chemotherapy is sometimes contraindicated, and radiotherapy alone becomes the only option. We retrospectively investigated the clinical outcomes of primary CNS lymphoma patients treated with radiotherapy alone.
Materials and methods
Between 1983 and 2006, 35 patients (median age 69 years, range 37–89 years) with primary CNS lymphoma were treated with radiotherapy alone. Of these, 74 % had an Eastern Cooperative Oncology Group performance status (PS) of 2–4. Most patients (91 %) received whole-brain irradiation with or without irradiation boost to the tumor site (median dose 50 Gy, range 22–50 Gy); remaining patients received partial brain irradiation.
Results
Median follow-up time was 20 (range 1–152) months, median survival time was 20 months, and the 1- and 2-year overall survival rates were 65 and 32 %, respectively. Median survival in patients aged <70 and ≥70 years was 26 and 10 months, respectively (p = 0.01).
Conclusion
Median survival with radiotherapy alone was 20 months. Patients aged <70 years have a better prognosis than those ≥70 years.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahluwalia MS, Peereboom DM. Primary central nervous system lymphoma. Curr Treat Options Neurol. 2010;12:347–59.
Ishikawa H, Hasegawa M, Tamaki Y, Hayakawa K, Akimoto T, Sakurai H, et al. Comparable outcomes of radiation therapy without high-dose methotrexate for patients with primary central nervous system lymphoma. Jpn J Clin Oncol. 2003;33:443–9.
Yamaguchi M, Ogawa S, Nomoto Y, Oka K, Taniguchi M, Nakase K, et al. Treatment outcome of nasal NK-cell lymphoma: a report of 12 consecutively-diagnosed cases and a review of the literature. J Clin Exp Hematopathol. 2001;41:93–9.
Niibe Y, Hayakawa K, Kitano M, Ishiyama H, Nakayama M, Yao K, et al. Successful treatment of concurrent chemoradiotherapy for stage I nasal NK/T cell lymphoma: a report of two cases. Anticancer Res. 2005;25:4403–6.
DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation Therapy Oncology Group Study 93–10. J Clin Oncol. 2002;20:4643–8.
Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266–72.
Shibamoto Y, Ogino H, Suzuki G, Takemoto M, Araki N, Isobe K, et al. Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985–2004. Neuro Oncol. 2008;10:560–8.
Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711–5.
Panageas KS, Elkin EB, Ben-Porat L, DeAngelis LM, Abrey LE. Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer. 2007;110:1338–44.
Murray K, Kun L, Cox J. Primary malignant lymphoma of the central nervous system. J Neurosurg. 1986;65:600–7.
Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25:4730–5.
Jahnke K, Korfel A, Martus P, Weller M, Herrlinger U, Schmittel A, et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol. 2005;16:445–9.
Ng S, Rosenthal MA, Ashley D, Cher L. High-dose methotrexate for primary CNS lymphoma in the elderly. Neuro Oncol. 2000;2:40–4.
Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG 83–15). Int J Radiat Oncol Biol Phys. 1992;23:9–17.
Littman P, Wang CC. Reticulum cell sarcoma of the brain. A review of the literature and a study of 19 cases. Cancer. 1975;35:1412–20.
Rampen FH, van Andel JG, Sizoo W, van Unnik JA. Radiation therapy in primary non-Hodgkin’s lymphomas of the CNS. Eur J Cancer. 1980;16:177–84.
Letendre L, Banks PM, Reese DF, Miller RH, Scanlon PW, Kiely JM. Primary lymphoma of the central nervous system. Cancer. 1982;49:939–43.
Mendenhall NP, Thar TL, Agee OF, Harty-Golder B, Ballinger WE Jr, Million PR. Primary lymphoma of the central nervous system. Cancer. 1983;52:1993–2000.
Gonzalez DG, Schuster-Utterhoeve LJ. Primary non-Hodgkin’s lymphoma of the central nervous system. Cancer. 1983;51:2048–52.
Sagerman RH, Collier CH, King G. Radiation therapy of microgliomas. Radiology. 1983;149:567–70.
Loeffler JS, Ervin TJ, Mauch P, Skarin A, Weinstein HJ, Canellos G, et al. Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival. J Clin Oncol. 1985;3:490–4.
Freeman CR, Shustik C, Brisson ML, Meagher-Villemure K, Dylewski I. Primary lymphoma of the central nervous system. Cancer. 1986;58:1106–11.
Shibamoto Y, Tsutsui K, Dodo Y, Yamabe H, Shima N, Abe M. Improved survival rate of primary intracranial lymphoma treated by high dose radiation and systemic vincristine–doxorubicin–cyclophosphamide–prednisolone chemotherapy. Cancer. 1990;65:1907–12.
Acknowledgments
Part of this study was presented at the 48th annual meeting of the Japan Society of Clinical Oncology.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Taguchi, S., Hamamoto, Y., Fujii, T. et al. Prognosis of primary central nervous system lymphoma treated with radiotherapy alone. Jpn J Radiol 30, 806–810 (2012). https://doi.org/10.1007/s11604-012-0124-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11604-012-0124-1